Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: Bendamustine
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Placebo
Drug: PCI-32765 (Ibrutinib)

First Posted Date: 2013-11-01

Last Posted Date: 2024-08-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 403

Registration Number: NCT01974440

Abiraterone Acetate for Castrate Resistant Prostate Cancer

Not Applicable

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2013-10-11

Last Posted Date: 2024-05-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT01961843

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Adenocarcinoma of the Prostate
Stage IV Prostate Cancer
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer

Interventions: Drug: enzalutamide
Drug: abiraterone
Drug: prednisone

First Posted Date: 2013-09-24

Last Posted Date: 2023-09-28

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 1311

Registration Number: NCT01949337

Locations: 🇺🇸
Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States

and more 533 locations

Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus
SLE

Interventions: Drug: Mycophenolate Mofetil
Drug: Hydroxychloroquine or Chloroquine
Drug: Prednisone

First Posted Date: 2013-09-20

Last Posted Date: 2020-08-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 102

Registration Number: NCT01946880

Locations: 🇺🇸
UCSD, San Diego, California, United States
🇺🇸
UCSF School of Medicine, San Francisco, California, United States
🇺🇸
University of Miami Hospitals and Clinics, Miami, Florida, United States

and more 16 locations

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone Acetate
Drug: Prednisone
Drug: Enzalutamide
Drug: LHRHa

First Posted Date: 2013-09-19

Last Posted Date: 2019-12-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT01946165

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate
Drug: Prednisone

First Posted Date: 2013-09-12

Last Posted Date: 2020-12-09

Lead Sponsor: Duke University

Target Recruit Count: 100

Registration Number: NCT01940276

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Birmingham VA Medical Center, Birmingham, Alabama, United States
🇺🇸
Tulane Cancer Center, New Orleans, Louisiana, United States

and more 11 locations

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2

Terminated

Conditions: Lymphoma, B-cell
Lymphoma, Large B-cell, Diffuse

Interventions: Drug: brentuximab vedotin
Drug: rituximab
Drug: cyclophosphamide
Drug: vincristine
Drug: prednisone
Drug: doxorubicin

First Posted Date: 2013-08-20

Last Posted Date: 2018-06-21

Lead Sponsor: Seagen Inc.

Target Recruit Count: 87

Registration Number: NCT01925612

Locations: 🇺🇸
Mid Ohio Oncology/Hematology Inc, Columbus, Ohio, United States
🇺🇸
Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Johns Hopkins Medical Center, Baltimore, Maryland, United States

and more 48 locations

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Phase 1

Completed

Conditions: B-cell Adult Acute Lymphoblastic Leukemia
Acute Leukemias of Ambiguous Lineage
Recurrent Adult Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Recurrent Adult Burkitt Lymphoma

Interventions: Drug: cyclophosphamide
Drug: vincristine sulfate
Drug: prednisone
Biological: inotuzumab ozogamicin
Other: laboratory biomarker analysis

First Posted Date: 2013-08-19

Last Posted Date: 2023-05-03

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 50

Registration Number: NCT01925131

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

and more 2 locations